Clear cell renal cell carcinoma (ccRCC) is one of few cancers with rising incidence in North America. The prognosis of ccRCC is variable and difficult to predict. Stratification of patients according to disease aggressiveness can significantly improve patient management.
We investigated the expression of the S100A11 protein in 385 patients with primary ccRCC using immunohistochemistry on tissue microarrays. We compared its expression with clinicopathologic parameters and patients' survival. We also validated our results at the mRNA level on an independent set from The Cancer Genome Atlas. As a dichotomous variable (low vs. high expression), there was a significant association between S100A11 expression and tumor grade, with higher expression associated with higher tumor grades (p < 0. 001). High expression was also significantly more frequently seen in higher versus lower stages (56 vs. 28 %). In the univariate analysis, high S100A11 expression was associated with significantly shorter disease-free survival (DFS) (HR = 2. 28; p = 0. 001). This was maintained in the multivariate analysis (HR = 1. 69; p = 0. 042). Expression was not associated with overall survival (OS) (p = 0. 10). Comparable results were obtained when S100A11 expression was analyzed as a trichotomous variable (low, moderate, or high expression). The Kaplan-Meier survival analyses showed that higher S100A11 expression was associated with statistically significant decrease in DFS (p < 0. 001), but not OS (p = 0. 1).
Clinical & experimental metastasis. 2015 Oct 15 [Epub ahead of print]
Manal Gabril, Hala Girgis, Andreas Scorilas, Fabio Rotondo, Samantha Wala, Georg A Bjarnason, Qiang Ding, Andrew Evans, Eriny Tawedrous, Maria Pasic, Antonio Finelli, Sahar Al-Haddad, George M Yousef
Department of Pathology and Laboratory Medicine, London Health Sciences Centre, Western University, London, N6G 2V4, Canada. , Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, M5B 1T8, Canada. , University of Athens, 30 Panepistimiou Street, 106 79, Athens, Greece. , Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, M5B 1T8, Canada. , Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, M5B 1T8, Canada. , Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Center, Toronto, ON, M4N 3M5, Canada. , Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, M5B 1T8, Canada. , Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, M5S 1A8, Canada. , Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, M5B 1T8, Canada. , Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, M5B 1T8, Canada. , Division of Urologic Oncology, Department of Surgery, University Health Network, Princess Margaret Hospital, University of Toronto, Toronto, M5G 2M9, Canada. , Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, M5B 1T8, Canada. , Department of Laboratory Medicine and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, M5B 1T8, Canada.